Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Bibliografiska uppgifter
Huvudupphovsmän:	Cree, BAC, Bennett, JL, Kim, HJ, Weinshenker, BG, Pittock, SJ, Wingerchuk, DM, Fujihara, K, Paul, F, Cutter, GR, Marignier, R, Green, AJ, Aktas, O, Hartung, H-P, Lublin, FD, Drappa, J, Barron, G, Madani, S, Ratchford, JN, She, D, Cimbora, D, Katz, E
Materialtyp:	Journal article
Språk:	English
Publicerad:	Elsevier 2019

Liknande verk

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism
av: Ho Jin Kim, et al.
Publicerad: (2023-12-01)

Treatment of Neuromyelitis Optica: Review and Recommendations.
av: Kimbrough, D, et al.
Publicerad: (2012)

Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders
av: Chu-Yuan Lou, et al.
Publicerad: (2024-06-01)

Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
av: Dominik Lehrieder, et al.
Publicerad: (2023-11-01)

Treatment of neuromyelitis optica: Review and recommendations
av: Kimbrough, D, et al.
Publicerad: (2012)

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialResearch in context
av: Jeffrey L. Bennett, et al.
Publicerad: (2022-12-01)

A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report
av: Xuefen Chen, et al.
Publicerad: (2024-07-01)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
av: Jyh Yung Hor, et al.
Publicerad: (2020-06-01)

Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder
av: Benjamin Osborne, et al.
Publicerad: (2024-04-01)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
av: Pittock, S, et al.
Publicerad: (2019)

Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab
av: Linjun Cai, et al.
Publicerad: (2024-02-01)

Atypical presentations of neuromyelitis optica
av: Douglas Sato, et al.
Publicerad: (2011-10-01)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
av: Collongues, N, et al.
Publicerad: (2013)

A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sjögren’s syndrome and pancytopenia treated with inebilizumab
av: Shasha Li, et al.
Publicerad: (2024-06-01)

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
av: Jeffrey L. Bennett, et al.
Publicerad: (2024-10-01)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
av: Fujihara, K, et al.
Publicerad: (2014)

Treatment of neuromyelitis optica: an evidence based review
av: Douglas Sato, et al.
Publicerad: (2012-01-01)

Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review
av: Xiaoqian Song, et al.
Publicerad: (2025-01-01)

Neuromyelitis Optica
av: Goyal V, et al.
Publicerad: (2009-10-01)

Neuromyelitis optica
av: Jacob Anu, et al.
Publicerad: (2007-01-01)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
av: Achim Berthele, et al.
Publicerad: (2023-04-01)

Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: therapeutic implications
av: Romain Marignier, et al.
Publicerad: (2010-09-01)

Differential diagnosis of neuromyelitis optica spectrum disorders
av: Sung-Min Kim, et al.
Publicerad: (2017-07-01)

Racial differences in neuromyelitis optica spectrum disorder
av: Kim, S, et al.
Publicerad: (2018)

Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica
av: Laurie Baert, et al.
Publicerad: (2021-08-01)

The borderland of neuromyelitis optica.
av: Matthews, L, et al.
Publicerad: (2009)

Pregnancy and neuromyelitis optica
av: Qiu-ying MA, et al.
Publicerad: (2016-10-01)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
av: Kim, W, et al.
Publicerad: (2012)

The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
av: Philippe Nicolas, et al.
Publicerad: (2019-11-01)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
av: Mealy, M, et al.
Publicerad: (2014)

Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
av: Stacey L. Clardy, et al.
Publicerad: (2024-05-01)

Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
av: Douglas Kazutoshi Sato, et al.
Publicerad: (2014-06-01)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
av: Paul, F, et al.
Publicerad: (2007)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
av: Friedemann Paul, et al.
Publicerad: (2007-04-01)

Use of mitoxantrone in neuromyelitis optica.
av: Kitley, J, et al.
Publicerad: (2011)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
av: Elsone, L, et al.
Publicerad: (2012)

Prognosis of Relapsing Neuromyelitis Optica
av: J Gordon Millichap
Publicerad: (2003-03-01)

Neuromyelitis optica spectrum disorder
av: Simon Broadley, et al.
Publicerad: (2017-09-01)

Neuromyelitis Optica: Case Report
av: Deniz Tuncel, et al.
Publicerad: (2008-06-01)

Autoantibodies in patients with neuromyelitis optica
av: Xin FAN, et al.
Publicerad: (2016-10-01)